UB640
TargetsPCSK9/AGT
IndicationsHyperlipidaemia; Hypertension
ClinicalCN - Pre-PCC
TherapeuticsCardiovascular
ModalitiesNucleic Acid Therapeutics
Exclusive Summary
- • Hit the unmet needs: targeting patients with high LDL-C and high blood pressure.
- • In vivo PoC validated in NHP: at least comparable to combination efficacy and duration of Inclisiran and Zilebesiran.
Asset Materials
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →